BLS Pharmaceuticals Limited (ASX:BLS)
1.115
-0.025 (-2.19%)
Sep 2, 2026, 10:38 AM AEST
BLS Pharmaceuticals Revenue
BLS Pharmaceuticals had revenue of 31.15M AUD in the half year ending December 31, 2025, with 538.22% growth. This brings the company's revenue in the last twelve months to 47.95M, up 178.15% year-over-year. In the fiscal year ending June 30, 2025, BLS Pharmaceuticals had annual revenue of 29.28M with 203.66% growth.
Revenue (ttm)
47.95M
Revenue Growth
+178.15%
P/S Ratio
5.47
Revenue / Employee
n/a
Employees
n/a
Market Cap
262.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 29.28M | 19.64M | 203.66% |
| Jun 30, 2024 | 9.64M | 4.34M | 81.98% |
| Jun 30, 2023 | 5.30M | 4.84M | 1,042.88% |
| Jun 30, 2022 | 463.64K | -1.74M | -78.97% |
| Jun 30, 2021 | 2.20M | -130.94K | -5.61% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinogen Medical | 12.67M |
| Starpharma Holdings | 12.67M |
| Orthocell | 9.33M |
| Dimerix | 6.35M |
| Alterity Therapeutics | 5.33M |
| Tetratherix | 3.86M |
| Racura Oncology | 2.81M |
| Nyrada | 2.01M |